Asia Pacific Blood Irradiation Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Intravenous Laser Blood Irradiation, Transcutaneous Laser Blood Irradiation, and Extracorporeal Blood Irradiation), Indication (Acute Leukemia, Lymph

Asia Pacific Blood Irradiation Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Intravenous Laser Blood Irradiation, Transcutaneous Laser Blood Irradiation, and Extracorporeal Blood Irradiation), Indication (Acute Leukemia, Lymphoma, Solid Tumors, Pelvic Tumors, and Others), and End User (Hospitals, Blood Banks, Diagnostics Clinics, and Research Institutes)   

The blood irradiation market in Asia Pacific is expected to grow from US$ 7.48 million in 2022 to US$ 12.34 million by 2028. It is estimated to grow at a CAGR of 8.7% from 2022 to 2028.
Increasing Immunocompromised Population and Rising Incidences of Leukemia and Lymphoma Provide Opportunities for Market Growth
Immunity plays an important role in the well-being of every individual, and its status continues to fluctuate with age, lifestyle, and food habits. There has been significant growth in the immunocompromised population, particularly in developed economies. An increase in the cases of autoimmune disorders, Human Immunodeficiency Virus (HIV) infections, organ transplants, etc., and the increased use of immunosuppressants are among the major factors leading to the hike in this population. Moreover, there has been significant growth in leukemia and lymphoma incidence rates. Such a rise in the immunocompromised population and the rising prevalence of autoimmune disorders are expected to create ample opportunities for companies in the blood irradiation market in the coming years.

Market Overview

The Asia Pacific blood irradiation market is further segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The region is characterized by a mixed growth scenario, with some countries having complex macroeconomic and political environments. Nevertheless, positive initiatives by governments are bolstering economic growth in most of these countries. Developing economies such as China, India, and Indonesia are investing substantially in infrastructure and industrial developments. In Asia Pacific, China is the largest market for blood irradiation market. The growth of the market is primarily attributed to the growing healthcare industry, increasing developments by the market players, and favorable regulatory policies. Additionally, the excessive population in China coupled with the rise of blood related disorder prevalence is majorly driving the growth of the blood irradiation market in China and making it a prime market in the Asia Pacific region. Rapid socioeconomic progress has greatly affected the lifestyle in China. Consequently, owing to lifestyle changes, urbanization, and accelerated population aging, the risk of cardiovascular diseases (CVD) has increased. China had the highest number of heart disease deaths last year, followed by India, Russia, the United States and Indonesia. Thus, owing to huge patient population of various communicable and non-communicable diseases and research and development by the market players is expected to propel the demand of blood irradiation market in this country.
Asia Pacific Blood Irradiation Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Blood Irradiation Market Segmentation

The Asia Pacific blood irradiation market is segmented into type , indication, end user, and country.
Based on type, the Asia Pacific blood irradiation market is segmented into intravenous laser blood irradiation, transcutaneous laser blood irradiation, and extracorporeal blood irradiation. The intravenous laser blood irradiation segment registered the largest market share in 2022. Based on indication , the market is segmented into acute leukemia, lymphoma, solid tumors, pelvic tumors and others. The acute leukemia segment held the largest market share in 2022. Based on end user, the Asia Pacific blood irradiation market is segmented into hospitals, blood banks, diagnostics clinics, and research institutes. The hospital segment held the largest market share in 2022. Based on country, the market is segmented into China, Japan, India, Australia, South Korea and Rest of Asia Pacific. China dominated the market share in 2022. Hitachi, Ltd.; Best Theratronics Ltd.; Gilardoni S.p.A.; Typenex Medical; and Actemium are the leading companies operating in the blood irradiation market in Asia Pacific.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Blood Irradiation Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Blood Irradiation Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.